Remove 2021 Remove Documentation Remove Labelling
article thumbnail

FDA Issues Two Guidance Documents on Food Allergen Labeling Requirements

The FDA Law Blog

Food and Drug Administration (FDA) issued two guidance documents, one draft and one final, on food allergen labeling requirements. 1, 2023; The applicability of food allergen labeling requirements to specific products (e.g., 1, 2023; The applicability of food allergen labeling requirements to specific products (e.g.,

article thumbnail

Experts to come together for compliance event ‘validation ready’ global labeling systems  

pharmaphorum

exploring ‘validation ready’ global labeling systems . ? . A group of industry experts is set to explore how medical device, clinical trial and pharmaceutical companies can proactively manage labeling risk. The post Experts to come together for compliance event ‘validation ready’ global labeling systems appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Transition Plans for Covid-19 Products are Amongst CDRH FY2023 Priorities

The FDA Law Blog

Amongst CDRH’s highest prioritized device guidance documents are final versions of the transition plans for medical devices that fall within enforcement policies or that were issued emergency use authorizations (EUAs) during Covid-19 public health emergency (PHE). They are also open to information to include in these guidance documents.

article thumbnail

MHRA publishes guidance on medicine regulation after Brexit

pharmaphorum

The guidance published on the Medicines and Healthcare products Regulatory Agency (MHRA) website is broadly similar to arrangements laid out in a Brexit “no deal” document published last year. Companies face significant changes in how the complex environment for medicines regulations will operate in 2021. “If

article thumbnail

What is Special about September 24, 2023 for the UDI System?

The FDA Law Blog

Such codes need to be placed on device labels and packages to allow devices to be easily identified and tracked throughout their lifecycle, except where the rule provided for an exception or alternative. The compliance dates were first published in 2013, and subsequently updated in various guidance documents and regulations published by FDA.

article thumbnail

Pharmacovigilance deep dive: risk minimisation measures

European Pharmaceutical Review

The sampling strategy must be supported by sound and properly cited sources whose conclusions must be presented as supportive elements in the study documents. The following four elements of sampling methodology were found to be under-documented in RMM effectiveness studies: Supporting documentation for country/region selection.

article thumbnail

Dupixent face rash and redness: Causes and treatment

The Checkup by Singlecare

Facial rashes and redness aren’t listed as adverse effects in Dupixent’s clinical trials, but they’re well-documented in case reports and other research. Clinical trials have proven Adbry to be effective in treating many cases of eczema without as many documented cases of facial dermatitis. Does Dupixent cause a face rash?